医药电商

Search documents
金石亚药涨2.00%,成交额5882.58万元,主力资金净流入146.07万元
Xin Lang Cai Jing· 2025-10-10 06:55
资金流向方面,主力资金净流入146.07万元,特大单买入0.00元,占比0.00%,卖出104.81万元,占比 1.78%;大单买入1234.20万元,占比20.98%,卖出983.32万元,占比16.72%。 10月10日,金石亚药盘中上涨2.00%,截至14:27,报9.68元/股,成交5882.58万元,换手率1.79%,总市 值38.89亿元。 金石亚药所属申万行业为:医药生物-化学制药-化学制剂。所属概念板块包括:医药电商、抗流感、中 药、零售药店、生物医药等。 截至6月30日,金石亚药股东户数2.28万,较上期增加14.00%;人均流通股15010股,较上期减少 12.28%。2025年1月-6月,金石亚药实现营业收入4.92亿元,同比减少5.80%;归母净利润6574.54万元, 同比增长67.71%。 分红方面,金石亚药A股上市后累计派现1.70亿元。近三年,累计派现7191.22万元。 责任编辑:小浪快报 金石亚药今年以来股价涨18.32%,近5个交易日涨0.73%,近20日跌3.49%,近60日跌3.39%。 今年以来金石亚药已经1次登上龙虎榜,最近一次登上龙虎榜为1月6日,当日龙虎榜净买 ...
华润三九涨2.05%,成交额2.96亿元,主力资金净流入1944.70万元
Xin Lang Zheng Quan· 2025-10-10 03:40
机构持仓方面,截止2025年6月30日,华润三九十大流通股东中,香港中央结算有限公司位居第二大流 通股东,持股4361.40万股,相比上期增加705.16万股。华泰柏瑞沪深300ETF(510300)位居第四大流 通股东,持股1193.47万股,相比上期增加356.72万股。易方达沪深300医药ETF(512010)位居第五大 流通股东,持股1096.93万股,相比上期增加185.89万股。易方达沪深300ETF(510310)位居第七大流 通股东,持股848.71万股,相比上期增加261.73万股。中欧医疗健康混合A(003095)退出十大流通股 东之列。 华润三九所属申万行业为:医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括:维生素、禽流感药物、医药 电商、抗流感、化妆品等。 截至9月20日,华润三九股东户数10.04万,较上期增加6.25%;人均流通股16561股,较上期减少 5.88%。2025年1月-6月,华润三九实现营业收入148.10亿元,同比增长4.99%;归母净利润18.15亿元, 同比减少24.31%。 分红方面,华润三九A股上市后累计派现100.69亿元。近三年,累计派现49.15亿元。 1 ...
马应龙涨2.04%,成交额8190.00万元,主力资金净流出63.57万元
Xin Lang Cai Jing· 2025-10-10 02:30
责任编辑:小浪快报 马应龙所属申万行业为:医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括:基因测序、医药电商、中药、 化妆品、民营医院等。 截至6月30日,马应龙股东户数3.11万,较上期减少23.07%;人均流通股13825股,较上期增加29.98%。 2025年1月-6月,马应龙实现营业收入19.49亿元,同比增长1.11%;归母净利润3.43亿元,同比增长 10.04%。 分红方面,马应龙A股上市后累计派现16.33亿元。近三年,累计派现5.91亿元。 机构持仓方面,截止2025年6月30日,马应龙十大流通股东中,香港中央结算有限公司位居第三大流通 股东,持股1239.12万股,相比上期增加13.24万股。交银新生活力灵活配置混合A(519772)位居第四 大流通股东,持股938.93万股,相比上期减少86.06万股。富国天惠成长混合(LOF)A/B(161005)位居 第五大流通股东,持股800.97万股,为新进股东。汇添富医药保健混合(470006)位居第九大流通股 东,持股448.64万股,为新进股东。交银新成长混合(519736)位居第十大流通股东,持股428.16万 股,相比上期减少88.39万股 ...
马应龙涨2.00%,成交额1.18亿元,主力资金净流入1516.41万元
Xin Lang Cai Jing· 2025-10-09 03:52
资金流向方面,主力资金净流入1516.41万元,特大单买入1892.06万元,占比16.07%,卖出119.71万 元,占比1.02%;大单买入2560.02万元,占比21.75%,卖出2815.97万元,占比23.92%。 马应龙今年以来股价涨5.85%,近5个交易日涨0.37%,近20日涨1.24%,近60日涨0.33%。 资料显示,马应龙药业集团股份有限公司位于湖北省武汉市武昌南湖周家湾100号,成立日期1994年5月 9日,上市日期2004年5月17日,公司主营业务涉及药品制造、医药零售及批发以及医疗服务等。主营业 务收入构成为:治痔类45.53%,零售、批发34.93%,其他16.43%,医院诊疗3.11%。 马应龙所属申万行业为:医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括:基因测序、医药电商、中药、 化妆品、民营医院等。 10月9日,马应龙盘中上涨2.00%,截至11:20,报26.98元/股,成交1.18亿元,换手率1.02%,总市值 116.30亿元。 截至6月30日,马应龙股东户数3.11万,较上期减少23.07%;人均流通股13825股,较上期增加29.98%。 2025年1月-6月,马应 ...
华人健康跌0.86%,成交额4027.14万元,近3日主力净流入-1036.09万
Xin Lang Cai Jing· 2025-09-30 09:05
来源:新浪证券-红岸工作室 9月30日,华人健康跌0.86%,成交额4027.14万元,换手率2.12%,总市值50.64亿元。 异动分析 医药电商+医疗器械概念+养老概念+阿里巴巴概念+创新药 1、据2023年2月17日互动易回复:公司除阿里旗下的天猫/饿了么平台外,公司在京东/拼多多/美团等国 内主要电商平台也都有布局,并且报告期内取得了长足发展。 2、安徽华人健康医药股份有限公司的主营业务是从事医药零售、代理及终端集采业务。公司的主要产 品是中成西药、中药饮片、保健品、医疗器械、特色原料。 资金分析 今日主力净流入-224.28万,占比0.06%,行业排名14/32,该股当前无连续增减仓现象,主力趋势不明 显;所属行业主力净流入-2.48亿,连续3日被主力资金减仓。 区间今日近3日近5日近10日近20日主力净流入-224.28万-1036.09万-301.80万-4945.41万-8468.28万 主力持仓 主力没有控盘,筹码分布非常分散,主力成交额2042.28万,占总成交额的2.04%。 技术面:筹码平均交易成本为14.02元 该股筹码平均交易成本为14.02元,近期该股有吸筹现象,但吸筹力度不强; ...
何氏眼科涨2.14%,成交额2400.67万元,主力资金净流出174.89万元
Xin Lang Cai Jing· 2025-09-30 06:57
Company Overview - He Eye Hospital Group, established on October 15, 2009, is located in Shenyang, Liaoning Province, and was listed on March 22, 2022 [1] - The company primarily provides specialized ophthalmic diagnosis and treatment services, with revenue composition as follows: Vision services 30.24%, Refractive surgery correction services 24.16%, Non-surgical treatment 20.02%, Cataract diagnosis and treatment services 13.68%, Vitreoretinal diagnosis and treatment services 8.09%, Other ophthalmic diagnosis and treatment services 3.20%, Other business income 0.61% [1] Financial Performance - As of June 30, 2025, He Eye Hospital reported operating revenue of 560 million yuan, a year-on-year decrease of 4.22%, while net profit attributable to shareholders was 44.32 million yuan, reflecting a year-on-year increase of 84.19% [2] - The company has distributed a total of 348 million yuan in dividends since its A-share listing, with 275 million yuan distributed over the past three years [3] Stock Performance - As of September 30, the stock price of He Eye Hospital increased by 2.14% to 21.03 yuan per share, with a total market capitalization of 3.323 billion yuan [1] - Year-to-date, the stock price has risen by 5.29%, with a 1.69% increase over the last five trading days, but a decline of 3.93% over the last 20 days and 3.53% over the last 60 days [1] - The number of shareholders increased by 15.03% to 10,800, while the average circulating shares per person decreased by 13.07% to 7,684 shares [2] Institutional Holdings - As of June 30, 2025, the sixth largest circulating shareholder is Rongtong Health Industry Flexible Allocation Mixed A/B (000727), holding 2.7947 million shares, a decrease of 1.7584 million shares compared to the previous period [3]
奥赛康涨2.03%,成交额1.89亿元,主力资金净流出1428.23万元
Xin Lang Cai Jing· 2025-09-30 03:05
Core Viewpoint - As of September 30, 2023, Aosaikang's stock price increased by 2.03% to 20.57 CNY per share, with a market capitalization of 19.092 billion CNY, despite a net outflow of main funds amounting to 14.2823 million CNY [1] Group 1: Stock Performance - Aosaikang's stock has risen by 63.38% year-to-date, but has seen a decline of 1.20% over the last five trading days and 11.83% over the last 20 days [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent occurrence on July 16 [1] Group 2: Financial Performance - For the first half of 2025, Aosaikang reported a revenue of 1.007 billion CNY, representing a year-on-year growth of 9.20%, and a net profit attributable to shareholders of 160 million CNY, which is a significant increase of 111.64% [2] - Cumulatively, Aosaikang has distributed 721 million CNY in dividends since its A-share listing, with 111 million CNY distributed over the past three years [3] Group 3: Shareholder Structure - As of September 20, 2023, Aosaikang had 20,000 shareholders, an increase of 2.46% from the previous period, with an average of 46,298 circulating shares per shareholder, down by 2.40% [2] - Notable changes in institutional holdings include the entry of Yongying Medical Innovation Mixed Fund as the sixth largest shareholder, holding 11.6856 million shares, and the exit of several funds from the top ten shareholders list [3]
融泰药业递表港交所 为中国院外医药市场第四大营销和供应链解决方案提供商
Zhi Tong Cai Jing· 2025-09-28 02:11
据招股书,融泰药业是中国领先的院外医药服务商,专注于数字化营销和供应链解决方案。根据弗若斯特 沙利文的资料,按2024年收入计,该公司是中国院外医药市场第四大营销和供应链解决方案提供商,以及 中国院外医药市场第一大面向个人客户的营销和供应链解决方案提供商。该公司自主开发了数字化精准营 销体系,并整合数字化业务及数据平台与智能物流基础设施,能为制药公司提供全流程全渠道医药销售解 决方案。该公司赋能上游制药公司在广阔而高度分散的院外医药市场中有效触达并服务终端客户,提高了 市场效率与可及性,驱动院外医药流通价值链扩展。 据港交所9月26日披露,广东融泰药业股份有限公司(简称:融泰药业)向港交所主板提交上市申请书,中信 证券为独家保荐人。 | 纂頂下的[編纂]數目 | … | [编纂]股H股(視乎[编纂]行使與否而定) | | --- | --- | --- | | [编纂]數目 | | [编纂]股H股(可予[编纂]) | | [编纂]數目 | … | [編纂]股H股(可予[編纂]及視乎[編纂]行使與否而 | | | | 定) | | 最高[编纂] | ። | 每股H股[編纂]港元(須於申請時以港元繳足,另 | | ...
华人健康跌1.01%,成交额4249.06万元,后市是否有机会?
Xin Lang Cai Jing· 2025-09-26 08:06
Core Viewpoint - The company, Anhui Huaren Health Pharmaceutical Co., Ltd., is actively expanding its presence in the health sector, particularly focusing on elderly care and innovative pharmaceutical products, while facing fluctuations in stock performance and market interest [2][3][8]. Company Overview - Anhui Huaren Health Pharmaceutical Co., Ltd. was established on June 29, 2001, and listed on March 1, 2023. The company primarily engages in pharmaceutical agency, retail, and terminal procurement, with its main revenue derived from traditional Chinese and Western medicine, accounting for 97.60% of total revenue [7]. - The company is located in Hefei, Anhui Province, and operates within the pharmaceutical and biological industry, specifically in the pharmaceutical commercial sector, focusing on offline pharmacies [7]. Business Strategy - The company is strategically positioning itself in the silver-haired health sector by providing chronic disease training and services through pharmacies, aiming to enhance health management for the elderly [2]. - It is developing a series of products targeting common diseases among the elderly, including the "Fuman Medical" series for cardiovascular health and the "Guojin" series of traditional Chinese medicine for health maintenance [2][3]. Financial Performance - For the first half of 2025, the company reported a revenue of 2.504 billion yuan, representing a year-on-year growth of 15.52%, and a net profit attributable to shareholders of 104 million yuan, up 42.17% from the previous year [8]. - The company has distributed a total of 80.02 million yuan in dividends since its A-share listing [8]. Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 45.15% to 26,100, with an average of 5,725 shares held per person, a decrease of 31.10% [8]. - Alibaba Health is the second-largest shareholder, holding 7.51% of the company, and there are collaborations with various Alibaba platforms [3][8]. Market Activity - On September 26, the company's stock price fell by 1.01%, with a trading volume of 42.49 million yuan and a market capitalization of 5.08 billion yuan [1]. - The stock has shown no clear trend in major net inflows, with a net outflow of 8.27 million yuan on the day [4][5].
九芝堂涨2.12%,成交额1.11亿元,主力资金净流入59.34万元
Xin Lang Cai Jing· 2025-09-26 03:29
Company Overview - JiuZhiTang has seen a stock price increase of 32.19% year-to-date, but has experienced a slight decline of 0.30% over the last 5 trading days and a more significant drop of 11.53% over the last 20 days [2] - The company specializes in the research, production, and sales of traditional Chinese medicine, biological pharmaceuticals, and cardiovascular drugs, with its main revenue sources being prescription drugs (50.27%) and OTC products (46.11%) [2] Financial Performance - For the first half of 2025, JiuZhiTang reported a revenue of 1.265 billion yuan, representing a year-on-year decrease of 24.71%, while the net profit attributable to shareholders was 144 million yuan, down 29.71% year-on-year [3] - Cumulative cash dividends since the company's A-share listing amount to 4.364 billion yuan, with 935 million yuan distributed over the past three years [4] Shareholder Information - As of June 30, 2025, the number of shareholders increased to 50,500, marking a 25.14% rise, while the average number of circulating shares per person decreased by 20.09% to 13,739 shares [3] - The top ten circulating shareholders include a new entrant, Qianhai Kaiyuan Steady Growth Mixed Fund, holding 1.996 million shares [4] Market Activity - On September 26, JiuZhiTang's stock rose by 2.12%, reaching 10.13 yuan per share, with a trading volume of 1.11 billion yuan and a turnover rate of 1.62% [1] - The net inflow of main funds was 593,400 yuan, with significant buying and selling activity recorded [1]